Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite and body weight, while tesamorelin is a growth hormone-releasing hormone analogue that stimulates pituitary GH release to reduce visceral fat, primarily in HIV-positive patients with lipodystrophy
Are there risks that require more frequent monitoring
2.3.9 Clinical chemistry Serum concentrations of the following parameters were determined photometrically using the automated analyzer Indiko Plus (Thermo Fisher Scientific GmbH, Waltham, USA): albumin, cholesterol, glutamate dehydrogenase (GLDH), total protein, urea, alkaline phosphatase (ALP), and alanine aminotransferase (ALT)
This may, in part, underlie the enhanced weight loss efficacy of dual GIP and GLP-1R agonists when compared with GLP-1R monoagonists, as GIPR activation may recapitulate the postingestive effects of glucose to reduce subsequent food intake